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Huntington’s disease (HD) is an autosomal-dominant disor-
der characterised by neurodegeneration that leads to irre-
pressible motor dysfunction, cognitive decline and
psychiatric disturbances, progressive dementia and death
approximately 20 years after disease appearance (Zuccato
et al. 2010). HD results from an aberrantly expanded
repetition of a CAG nucleotide triplet in the huntingtin
(Htt) gene that produces a polyglutamine extension at the N-
terminus of the Htt protein (Huntington’s Disease Collabo-
rative Research Group 1993; Bates 2005). Although the
abnormal protein is ubiquitously expressed, cell degeneration
occurs mainly in the brain. Over the course of HD, the
degeneration of GABA-releasing spiny projection neurons in
the striatum is predominant; however, loss of neurons in
other brain regions, such as cerebral cortex has also been
reported (Zuccato et al. 2010). Htt is a large multi-domain
protein, whose function is still not fully understood but is
thought to have multiple distinct cellular roles, including
intracellular transport, synaptic function, anti-apoptotic
activity and transcriptional regulation (Cattaneo et al.
2005). However, much attention has focussed on the
transcriptional dysregulation that occurs in the presence of
mutant Htt (muHtt). Both wild-type and muHtt can interact
with a number of transcription factors such as cAMP-
response element binding protein-binding protein (Steffan
et al. 2000; Nucifora et al. 2001), TATA-binding protein
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Abstract
Transcriptional dysfunction is a prominent hallmark of Hun-
tington’s disease (HD). Several transcription factors have
been implicated in the aetiology of HD progression and one of
the most prominent is repressor element 1 (RE1) silencing
transcription factor (REST). REST is a global repressor of
neuronal gene expression and in the presence of mutant
Huntingtin increased nuclear REST levels lead to elevated
RE1 occupancy and a concomitant increase in target gene
repression, including brain-derived neurotrophic factor. It is of
great interest to devise strategies to reverse transcriptional
dysregulation caused by increased nuclear REST and deter-
mine the consequences in HD. Thus far, such strategies have
involved RNAi or mutant REST constructs. Decoys are dou-
ble-stranded oligodeoxynucleotides corresponding to the
DNA-binding element of a transcription factor and act to
sequester it, thereby abrogating its transcriptional activity.
Here, we report the use of a novel decoy strategy to rescue
REST target gene expression in a cellular model of HD. We
show that delivery of the decoy in cells expressing mutant
Huntingtin leads to its specific interaction with REST, a
reduction in REST occupancy of RE1s and rescue of target
gene expression, including Bdnf. These data point to an
alternative strategy for rebalancing the transcriptional dysre-
gulation in HD.
Keywords: brain-derived neurotrophic factor, decoy oligo-
nucleotides, histone modification, Huntington’s disease,
repressor element 1 silencing transcription factor, transcrip-
tional dysregulation.
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(Huang et al. 1998), Sp1 (Dunah et al. 2002), p53 (Steffan
et al. 2000; Bae et al. 2005), transcription initiation factor
TFIID 130 kDa subunit (Dunah et al. 2002) and TATA-
binding protein (Huang et al. 1998) and these interactions are
frequently disrupted in the presence of muHtt (Rubinsztein
and Carmichael 2003). Recent work has highlighted repressor
element 1 (RE1) silencing transcription factor (REST) (also
known as neuron-restrictive silencing factor) as one tran-
scription factor, whose function is disrupted in HD (Zuccato
et al. 2003, 2007; Bithell et al. 2009; Johnson and Buckley
2009). REST was ﬁrst identiﬁed as a regulator of neuronal
genes in non-neuronal cells (Kraner et al. 1992; Mori et al.
1992; Schoenherr and Anderson 1995). Genome-wide chro-
matin immunoprecipitation (ChIP) and bioinformatic studies
have subsequently revealed several thousand genomic REST
binding loci (RE1 sites), which are linked to genes that
encode non-neuronal as well as neuronal proteins (Bruce
et al. 2004; Johnson et al. 2006, 2007, 2008a). Further,
REST regulates target genes in both neural progenitors
(Johnson et al. 2008a) and in mature neurons and glia (Palm
et al. 1998; Abrajano et al. 2009a,b). Indeed REST dysfunc-
tion in neurons has been implicated in several neurological
and neurodegenerative pathologies, including epileptic sei-
zure (Palm et al. 1998; Garriga-Canut et al. 2006; Spencer
et al. 2006), ischaemia (Calderone et al. 2003) and HD
(Zuccato et al. 2003, 2007; Buckley et al. 2010).
Previous work has shown that wild-type Htt can
sequester REST in the cytoplasm whereas in the presence
of muHtt, this association is disrupted and leads to
increased levels of nuclear REST resulting in increased
REST occupancy of RE1 sites and repression of target
genes (Zuccato et al. 2007). One key REST target gene that
is repressed in the presence of muHtt is Bdnf. Brain-derived
neurotrophic factor (BDNF) is supplied by cortical projec-
tions to the striatum where it is necessary for the
maintenance and survival of medium spiny projection
neurons, the most prominent neuronal population that dies
during HD (Altar et al. 1997; Canals et al. 2004; Zala et al.
2005; Zuccato and Cattaneo 2009). Several studies have
shown reduced BDNF levels in both animal and cellular
models of HD. These studies indicate that a decrease in
cortical BDNF occurs early in the disease process and is
followed by a progressive decline, strongly implicating the
role of this neurotrophin in HD pathology (Zuccato et al.
2001, 2007, 2008). REST occupancy of RE1 sites, includ-
ing at the Bdnf promoter, is increased in HD models
including Hdh109/109 knock-in and R6/2 mice (Zuccato
et al. 2007). Importantly, in the case of Hdh109/109 mice,
this increased occupancy precedes the development of a
neuropathological phenotype (Zuccato et al. 2007). This
suggests that dysregulation of REST target gene expression
might be an early molecular event in HD and thus
attenuating REST binding during early disease stages could
be of therapeutic beneﬁt.
Subsequently, we have shown that use of a dominant-
negative REST construct, comprising only the eight zinc
ﬁnger DNA-binding domain and lacking any co-repressor
interaction domains, can rescue BDNF levels (mRNA and
protein) in cellular models of HD (Zuccato et al. 2007).
Although such mutant constructs are useful tools, they are
large and require viral delivery for optimal results. An
alternative strategy is deployment of decoy oligodeoxynu-
cleotides (ODNs) that act as surrogate binding sites for
transcription factors and sequester the native transcription
factor from its genomic binding sites. Decoy ODNs have
been used successfully to inhibit the binding and transcrip-
tional action of several transcription factors including nuclear
factor-kappaB protein, Sp1, activator protein 1, signal
transducer and activator of transcription 1/3 and nuclear
factor of activated T-cells 1c (Griesenbach et al. 2002; Chae
et al. 2006; Stadlbauer et al. 2008). Furthermore, this
approach has been used to successfully deliver and attenuate
transcription factor function in neural cells in culture (Steiger
et al. 2004; Meller et al. 2005; Yao et al. 2005; Aharoni-
Simon et al. 2006), in brain slice preparations and in vivo (Ye
and Johnson 2001; Kubo et al. 2003; Dash et al. 2005). The
main limitation of unmodiﬁed ODNs is their susceptibility to
degradation by nucleases prevalent in sera and cells. To
rectify this problem, ODNs with modiﬁed linkages, such as
phosphorothiolate and methylphosphonate, have been devel-
oped (Lee et al. 2003; Osako et al. 2007). Here, we describe
the development of modiﬁed decoy ODNs to inhibit REST-
mediated gene repression in a cellular model of HD and
show efﬁcient rescue of aberrant gene expression.
Methods
Hdh109/109 and Hdh7/7 cell culture and transfection
Hdh7/7 and Hdh109/109 cell lines were previously generated from the
striata of wild-type and homozygous knock-in mice with each Htt
allele bearing 7 or 109 CAG repeats, respectively, as described by
Trettel et al. (2000). Both cell lines were propagated in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% foetal calf serum
at 33C in a humidiﬁed 5% CO2 atmosphere. Transfection with
ICAFectin (Eurogentec, Southampton, UK) was performed accord-
ing to manufacturer’s instructions and optimal transfection efﬁ-
ciency (50–60%) was achieved using 0.5 lg of DNA/lL of
ICAFectin. Transfections were carried out in the presence of serum
and medium was replaced after 12–24 h.
Construction of phosphorothiolated RE1 decoy ODN
Single stranded oligonucleotides were synthesised by Sigma
Genosys (St. Louis, MO, USA). Annealing was performed in 10·
annealing buffer (100 mM Tris-HCl, pH8.0, 10 mM EDTA, 1 M
NaCl) by heating to at least 5–10C above their Tm and cooling
slowly to 4C over 3–4 h using a heatblock. A RE1 decoy (++D)
was designed corresponding to a canonical REST-binding site
(Johnson et al. 2006). A negative decoy control ())D) was
generated using a sequence corresponding to a non-canonical RE1
Journal of Neurochemistry  2010 International Society for Neurochemistry, J. Neurochem. (2011) 116, 415–425
 2010 The Authors
416 | C. Soldati et al.
that has been shown not to bind REST (Bruce et al. 2004). The
decoy ODN sequences, including a phosphorothiolate modiﬁca-
tion on the ﬁrst three nucleotides were: Positive decoy (++D):
5¢-GpPpCpPTPTTCAGCACCACGGACAGCGCCAGC-3¢; Nega-
tive decoy ())D): 5¢-GpPpCpPTPTCCAGCACAGTGGTCAGA-
CCC-3¢.
DNA binding and electromobility shift assay (EMSA)
For gel shift analysis, 12.5 nM of infrared (IR700) ﬂuorescence-
labelled decoy (IR-Decoy) was incubate with 0.25 lg HeLa cell
nuclear extract in binding buffer (40 mM Tris-HCl, pH8, 0.4 mg/mL
bovine serum albumin, 200 nM ZnCl2, 400 mM KCl, 2 mM MgCl2,
40% glycerol, 0.4% NP-40, Sigma, St. Louis, MO, USA) and 2 mM
b-mercaptoethanol for 1 h at 4C in the dark. For supershift
experiments, 2 lL of anti-REST rabbit polyclonal (P-18X, 2 mg/
mL; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added to
the mixture. For excess negative decoy assays, 50 nM ﬁnal
concentration of negative decoy ())D) was added to the mixture.
Reaction mixtures were separated on a 4% non-denaturing poly-
acrylamide gel at 4C in 0.5· TBE (90 mM Tris borate, 2 mM
EDTA, pH8.3) at 150 V for 2 h at 4C in the dark. The gel was pre-
run at 150 V for30 min at 4C. Gels were scanned with an Odyssey
Infrared Imaging System (Li-cor, NE, USA). The decoy ODN
sequences used, including 5¢-/5IRD700 modiﬁcations, were 5¢-/
5IRD700/TTCAGCACCACGGACAGCGCC-3¢ and 5¢-/5IRD700/
GGCGCTGTCCGTGGTGCTGAA-3¢ (Integrated DNA Technolo-
gies, Belgium).
RNA extraction and cDNA synthesis
Total RNA was extracted from Hdh109/109 and Hdh7/7 cells using
Trizol (Invitrogen, Carlsbad, CA, USA) and digested with DNAse I
(Ambion, Austin, TX, USA). For each RNA sample, 2 lg of total
RNA was reverse transcribed for 60 min at 37C with random
hexamers (Promega, Madison, WI, USA) and Moloney murine
leukemia virus reverse transcriptase (Promega, WI, USA).
Real-time PCR and quantification of gene expression
Polymerase chain reactions were run with the following condition:
95C for 3 min, then 45 cycles · (30 s 95C, 30 s 60C, 30 s
72C). Real-time PCR was performed using iQ SYBR Green
Supermix (Bio-Rad Laboratories, Hercules, CA, USA) with 0.5 lM
primers. Expression levels were analysed according to the Pfafﬂ
method (Pfafﬂ et al. 2002) and then normalised to levels of Gapdh.
Error bars show the standard deviations obtained from two samples
run in triplicate in two different assays. Primer sequences – Gapdh
(Fwd: 5¢-TCCGACTTCAACAGCAACTC-3¢; Rev: 5¢-CTTGCT-
CAGTGTCCTTGCTG-3¢); REST (Fwd: 5¢-CGAACTCACACAG-
GAGAACG-3¢; Rev: 5¢-GAGGCCACATAATTGCACTG-3¢); M4
muscarinic receptor gene (Chrm4) (Fwd: 5¢-TCCTCACCTGGAC-
ACCCTAC-3¢; Rev: 5¢-ACGTAGCAGAGCCAGTAGCC-3¢); Bdnf
(Fwd: 5¢-TCGTTCCTTTCGAGTTAGCC-3¢; Rev: 5¢-TTGGTA-
AACGGCACAAAACA-3¢); synapsin 1 (Syn1) (Fwd: 5¢-GAG-
CAGATTGCCATGTCTGA-3¢; Rev: 5¢-CACTGCGCAGATGTCA-
AGTC-3¢).
Chromatin immunoprecipitation
Cells were ﬁxed in 1% formaldehyde at 20–25C for 5 min before
washing in cold phosphate-buffered saline and centrifugation at
2200 g for 5 min. Cells were lysed in lysis buffer for 30 min on ice,
cell nuclei pelleted and resuspended in shearing buffer before
sonication in a Bioruptor (Diagenode, Belgium) to obtain an average
chromatin shear size of 200–500 bp. All steps included protease
inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN,
USA). Pre-cleared chromatin (20 lg) was immunoprecipitated with
1–2 lg of antibody at 4C for 3 h and 25 lL magnetic protein-G
beads (Active Motif, Carlsbad, CA, USA) was added for 1 h at 4C
before magnetic capture. Following a series of washes, eluted
chromatin was de-crosslinked, proteinase K-treated and ChIP DNA
was puriﬁed using QIAquick PCR puriﬁcation kit (Qiagen,
Valencia, CA, USA). Eluted ChIP DNA was analysed using
quantitative PCR (qPCR). An anti-REST rabbit polyclonal antibody
(Millipore Corporation, Bedford, MA, USA) was used to precipitate
chromatin. Non-speciﬁc binding was assessed by immunoprecipi-
tation with non-immune rabbit IgG and enrichments were norma-
lised to those at the Chrm4 coding region, a locus greater than 10 kb
distal to any known RE1 site. RE1 ﬂanking primer sequences were
as follows: Bdnf RE1 [Fwd: 5¢-GGATTTGTCCGAGGTGGTAG-
3¢; Rev: 5¢-CGGAAAAGACGCTTTTTAAGG-3¢ (these primers are
designed to amplify exon 2, present in all Bdnf transcripts)]; Syn1
RE1 (Fwd: 5¢-GCACACTCAGAGGGGAACAT-3¢; Rev: 5¢-CTCT-
TTTCTTTGCCCGACAG-3¢); Chrm4 RE1 (Fwd: 5¢-AGGAGA-
CTCGTGCCATCTTC-3¢; Rev: 5¢-CGAGCATCTACCCTGGCT-
AA-3¢).
Immunocytochemistry
Cells were ﬁxed for 10 min in 4% paraformaldehyde, permeabilised
in 0.1% Triton X-100 (Sigma) for 5 min then incubated with anti-
REST (1 : 200; Upstate Biotechnology, Lake Placid, NY, USA) for
1 h at 20–25C in phosphate-buffered saline containing 10% normal
goat serum. Secondary antibody incubation was performed for
30 min at 20–25C with Cy5-conjugated rabbit anti-goat IgG
(1 : 500; Jackson Labs, CA, USA). Nuclei were counter-stained
with 4¢,6-diamidino-2-phenylindole (DAPI) and coverslips were
mounted in Floromount-G (Southern Biotech, AL, USA).
BDNF ELISA assays
Cell lysates were prepared in lysis buffer consisting of 10%
glycerol, 25 mM Tris HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100,
5 mM EDTA and 1 mM EGTA supplemented with 1 : 100 Protease
Inhibitor Mixture (Sigma-Aldrich, St Louis, MO, USA). Samples
were homogenised, sonicated and centrifuged at maximum speed for
15 min at 4C. The supernatants were collected and stored at
)30C. Samples were assayed for BDNF using the ImmunoAssay
System (Promega) according to manufacturer’s instructions.
Nuclear and cytoplasmic western blotting
Cytoplasmic and nuclear protein fractions were extracted using NE-
PER Nuclear and Cytoplasmic extraction reagents (Thermo scien-
tiﬁc, MA, USA) with protease inhibitors (Protease Inhibitor
Cocktail; Roche) according to manufacturer’s instructions. Protein
concentrations were determined using a Bicinchoninic Acid Kit
(Sigma) and a Tecan plate reader with Magellan5 software (Tecan,
Switzerland). Fifty microgram of nuclear or cytoplasmic protein for
each sample was boiled for 5 min in Laemmli sample buffer and run
on 6% sodium dodecyl sulphate–polyacrylamide gels. Proteins were
transferred to polyvinylidene diﬂuoride membrane using a Mini
 2010 The Authors
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Trans-Blot system (Bio-Rad) before blocking in 1· Tris-buffered
saline with 0.1% Tween-20 with 5% skimmed-milk for 1 h at 20–
25C. Membranes were then incubated with rabbit anti-REST
(Millipore, 1 : 2000), mouse anti-actin (1 : 2000; Abcam, UK) or
rabbit anti-RNA Polymerase II (PolIIS5, 1 : 2000; Abcam) followed
by goat anti-rabbit horseradish peroxidase (1 : 7500; Santa Cruz) or
goat anti-mouse horseradish peroxidase (1 : 2000; Dako, Carpinte-
ria, CA, USA) secondary antibodies. Chemiluminescence was
performed using Lumi-Light Western Blot Substrate and Lumi-
Film (Roche) developed using a CompactX4 X-ray developer.
Membranes were stripped between detections using a Re-Blot Plus
Kit (Chemicon) according to manufacturer’s instructions.
Results
Changes in gene and protein expression following decoy
ODN delivery in Hdh109/109 cells
Hdh109/109 cells provide an ideal model system in which to
test the effect of a decoy ODN on REST-mediated gene
dysregulation since these cells have reduced BDNF mRNA
and protein levels compared with Hdh7/7 cells and show de-
repression of Bdnf and other REST target genes following
infection with a dominant-negative REST (DN : REST)
adenovirus (Zuccato et al. 2007). Compared with wild-type
Hdh7/7 cells, mutant Hdh109/109 cells displayed increased
nuclear localisation of REST by both immunoﬂuorescence
(Fig. 1a) and nuclear and cytoplasmic fraction western
blotting (Fig. 1b) as previously reported (Zuccato et al.
2003). To target REST function in this system, we designed a
decoy ODN (++D) that contained a canonical RE1 sequence,
which can be bound by the REST DNA-binding domain. We
additionally designed a negative control decoy ODN ())D)
carrying a non-canonical RE1 site that cannot be bound by
REST (Bruce et al. 2004). Both sense and antisense
oligonucleotides were synthesised with phosphorothiolate
bases at their 5¢-ends to protect against exonuclease action.
To demonstrate the efﬁcacy and speciﬁcity of the REST
decoy ODN, we investigated the expression of three REST
target genes: Bdnf, Chrm4 and Syn1 together with b-actin.
Bdnf, Chrm4 and Syn1 have all been shown to be aberrantly
repressed by REST in Hdh109/109 cells (Zuccato et al. 2007),
whereas b-actin is neither bound nor regulated by REST.
Hdh109/109 cells were transfected with the REST decoy
ODN (++D) or non-canonical decoy ())D) and expression
of Bdnf, Syn1, Chrm4 and Rest was analysed by qPCR in
untransfected Hdh7/7 and Hdh109/109 cells and in Hdh109/109
cells transfected with decoy ODNs 48 h following transfec-
tion (Fig. 1c). Bdnf, Syn1 and Chrm4 all showed signif-
icantly reduced expression in Hdh109/109 compared with
control Hdh7/7 cells. Hdh109/109 cells transfected with REST
decoy ODN showed signiﬁcant up-regulation of all three
REST target genes compared with untransfected cells and
compared with cells transfected with ))D (Fig. 1c). ))D
transfected cells showed no signiﬁcant change in expression
of Bdnf, Syn1 or Chrm4 compared with untransfected cells
(p-value = 0.11, 0.12 and 0.05, respectively). REST and
actin expression were unaltered in all conditions (Fig 1c).
The observed level of decoy-mediated de-repression of target
genes was comparable with that obtained using DN : REST
and Rest shRNA strategies (Figure S1). In addition, rescue of
Bdnf gene expression was accompanied by increased Bdnf
protein levels as measured by ELISA assays (Fig. 1d).
Untransfected Hdh109/109 cells expressed approximately 26%
of Hdh7/7 Bdnf levels but following delivery of REST decoy
ODN, Bdnf protein levels were signiﬁcantly increased to
65% of wild-type levels (Fig. 1d, ++D) compared with levels
following negative decoy ())D) transfection. Our results,
therefore, indicate that by attenuating REST binding with
modiﬁed decoy ODNs, it is possible to de-repress multiple
REST target genes and to partially restore Bdnf protein levels
in HD cells.
REST occupancy of RE1s following decoy ODN delivery
To directly test whether treatment with decoyODNs decreased
occupancy of REST at its RE1 targets in the genome, we
carried out ChIP-qPCR analysis using anti-REST IgG and
primers that ﬂank RE1 sites of the Bdnf, Syn1 and Chrm4
genes (Fig. 2). Chromatin from decoy-transfected cells (++D
or ))D) was collected 48 h post-transfection, similar to gene
and protein expression analyses described above earlier, since
this time-point showed the highest level of efﬁcacy in rescue
of target gene expression (data not shown). REST occupancy
was assessed at three REST target gene RE1s: Bdnf, Syn1 and
Chrm4 (Fig. 2). Higher levels of REST occupancy were seen
at all three loci in untransfected Hdh109/109 cells compared
with Hdh7/7 cells, consistent with the higher levels of REST
seen in Hdh109/109 cells. No change in REST occupancy was
detected in cells transfected with the negative decoy (Fig. 2,
))D). However, following delivery of the Rest RE1 decoy
ODN, REST occupancy was signiﬁcantly decreased at all
three loci in Hdh109/109 cells to essentially wild-type (Hdh7/7)
levels (Fig. 2, ++D).We again performed parallel experiments
using DN : REST and Rest shRNA for comparison and
showed that RE1 decoy ODN was equally as effective at
decreasing REST recruitment to these RE1s (Figure S2).
Therefore, modiﬁed decoy ODNs that contain an RE1
consensus binding site are able to sequester REST protein
from target RE1 sites in the genome, resulting in decreased
Rest occupancy at several target genes, including Bdnf.
Changes to histone acetylation of RE1s following decoy
delivery
Transcriptionally active or transcriptionally silent chromatin
states are accompanied by speciﬁc histone amino-terminal
modiﬁcations conferring distinct epigenetic signatures (for
review, see Jenuwein and Allis 2001). Numerous studies have
demonstrated that REST is able to maintain low levels of
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histone H3 lysine 9 acetylation (H3K9ac), an epigenetic
marker associated with active chromatin (Dhalluin et al.
1999), at the promoter region of target genes via recruitment
of histone deacetylase (HDAC) activity (Grimes et al. 2000;
Roopra et al. 2000). To better understand the mechanisms of
REST silencing and repression in Hdh7/7 and Hdh109/109 cells,
we looked at H3K9ac levels around the RE1s in response to
changing RESToccupancy using our decoy strategy. Figure 3
shows ChIP-qPCR analysis of H3K9ac levels of REST target
genes in untransfected Hdh7/7 and Hdh109/109 cells and
Hdh109/109 cells 48 h following delivery of decoy ODNs
(++D or ))D). Bdnf and Chrm4 showed more than twofold
and Syn1 almost 1.8-fold lower enrichments of H3K9ac in
Hdh109/109 cells compared with Hdh7/7 cells (Fig. 3, all
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Fig. 1 De-repression of repressor element 1 (RE1) silencing tran-
scription factor (REST) targets and rescue of brain-derived neuro-
trophic factor (BDNF) protein levels using RE1 decoy oligonucleotides
(ODNs). (a) Localisation of REST protein in Hdh7/7 and Hdh109/109
cells visualised by immunofluorescence (using anti-REST antibody)
and (b) western blot of nuclear and cytoplasmic protein fractions
(using anti-REST antibody for both and either anti-RNA polymerase II
serine 5 or anti-actin for loading controls respectively). REST is much
more highly localised to the nucleus in Hdh109/109 cells compared with
Hdh7/7 cells. (c) Bdnf, Syn1 and Chrm4 mRNA levels were measured
in Hdh7/7 and Hdh109/109 cells following delivery of REST decoy ODN
(++D) or negative decoy ODN ())D). All three show reduced
expression in Hdh109/109 compared with Hdh7/7 and were increased
beyond Hdh7/7 levels in Hdh109/109 transfected with ++D compared
with untransfected cells and cells transfected with ))D. Data are ex-
pressed as percentage of expression relative to Hdh7/7 cell levels and
represent the average of three independent experiments. (d) Bdnf
protein levels were determined by ELISA on lysates from untrans-
fected Hdh7/7 and Hdh109/109 cells and Hdh109/109 cells transfected with
++D or ))D. Data are the average of two independent experiments.
In (a) scale bar = 20 lm. For (b) and (c) *p £ 0.05, **p £ 0.01,
***p £ 0.001 [using Student’s t-test in (b) and one-way ANOVA in (c)]
and error bars show SDs.
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p £ 0.05 using Student’s t-test). We observed a signiﬁcant
increase in H3K9ac enrichments at all three loci, to essentially
wild-type levels or greater, following REST decoy ODN
delivery (++D) compared with untransfected or with negative
decoy ODN ())D) transfected cells (Fig. 3, all p £ 0.05).
Our results indicate that REST is able to maintain low levels
of H3K9ac around REST binding sites. We also show that
regulation of the local chromatin environment is associated
with levels of REST occupancy and reduced H3K9ac
observed in Hdh109/109 cells can be restored by the use of
modiﬁed decoy ODN technology.
RE1-containing decoy ODN interact directly with of REST
To demonstrate a direct interaction between REST and the
speciﬁc REST RE1 decoy ODN we performed an EMSA
with a ﬂuorescent (5¢-IRD700) labelled decoy ODN (Fig. 4,
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Fig. 3 Effect of decoy delivery on histone H3 acetyl-lysine 9 (H3K9ac)
levels at repressor element 1 (RE1) sites. Chromatin immunoprecipi-
tation (ChIP)-quantitative PCR (qPCR) analysis at three known RE1
loci in untransfected wildtype (Hdh7/7) and mutant (Hdh109/109) cells
and in mutant cells after delivery of canonical RE1-containing decoy
(++D) or a negative decoy ())D). H3K9ac enrichments in ++D
transfected Hdh109/109 cells at Bdnf, Syn1 and Chrm4 RE1s were in-
creased to wild-type levels (Hdh7/7). H3K9ac enrichment values are
shown normalised to total H3 enrichment to account of any variation in
nucleosomal density.
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Fig. 4 Decoy oligonucleotides (ODNs) interact directly with repressor
element 1 (RE1) silencing transcription factor (REST) protein. The
figure shows a fluorescence western blot image with visualisation of an
infra-red fluorescence-labelled decoy ODNs containing an RE1-bind-
ing site known to bind REST protein (IR-Decoy ++D). The following
samples were loaded in duplicate: IR-Decoy ++D alone (lanes 1 and
2); IR-Decoy ++D incubated with HeLa nuclear extract (lanes 3 and 4);
IR-Decoy ++D incubated with HeLa nuclear extract and anti-Rest IgG
(lanes 5 and 6); HeLa nuclear extract incubated with anti-Rest IgG
and excess, non-specific (un-labelled) Decoy ODNs ())D). Free
(unbound) IR-Decoy +DD is shown in the bottom panel and alone
serves as a negative control (lanes 1 and 2). Incubation of IR-Decoy
++D with HeLa nuclear extract shows an additional band shifted to a
higher molecular weight corresponding to a complex of REST protein
and IR-Decoy ++D (REST : IR-Decoy). The presence of REST in this
complex is confirmed by the super-shifted bands of complexes
co-incubated with anti-Rest IgG (lanes 5–6). The REST : IR-Decoy
complex is able to form even in the presence of excess quantities of a
non-specific, un-labelled decoy containing an RE1 that does not bind
to REST (Decoy ))D, lanes 7 and 8).
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Fig. 2 Repressor element 1 (RE1) silencing transcription factor
(REST) occupancy in response to decoy delivery. Chromatin
immunoprecipitation (ChIP)-quantitative PCR (qPCR) analysis at
three known RE1 sites in untransfected wild-type (Hdh7/7) and mu-
tant (Hdh109/109) cells and in mutant cells following delivery of
canonical RE1-containing decoy (++D) or a non-REST binding RE1-
containing decoy ())D). REST occupancy of the Bdnf, Syn1 and
Chrm4 RE1 loci was decreased in Hdh109/109 cells transfected with
++D compared with untransfected cells and those transfected with
))D. Data show REST enrichment relative to both enrichment at a
non-specific region that does not contain an RE1 site and to input
levels and represent the average of three independent experiments,
error bars show SDs, **p £ 0.01, ***p £ 0.001 (using Student’s t-
test).
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IR-Decoy ++D). The IR-Decoy was incubated with or
without HeLa cell nuclear extract and the binding reactions
were run on a native polyacrylamide gel. Incubation of the
decoy with HeLa cell nuclear extract resulted in a speciﬁc
band shift corresponding to a protein : decoy (REST : IR-
Decoy) interaction (Fig. 4, lanes 3–4). Inclusion of speciﬁc
anti-REST IgG resulted in a supershift of the protein : decoy
complex (Fig. 4, lanes 5–6) that conﬁrmed that complexes
shown by the band shifts in lanes 3 and 4 contained REST
protein. Moreover, REST : IR-Decoy complexes were not
disrupted when binding reactions were co-incubated with
excess negative decoy (Fig. 4, lanes 7–8, ))D). The EMSA
assays conﬁrm the ability and speciﬁcity of the modiﬁed
REST RE1 decoy ODNs to directly interact with REST
protein. Therefore, the observed changes to REST target
gene expression, protein expression, REST occupancy and
the local chromatin environment in Hdh109/109 cells follow-
ing introduction of ++D can be attributed to ++D speciﬁc
sequestration of REST protein.
Discussion
Use of modiﬁed decoy ODNs to abrogate the action of
transcription factors is a promising approach to rescuing
phenotypic defects because of aberrant transcription factor
function. In this work, we have developed a decoy strategy to
block the activity of REST based on its binding of the
conserved 21bp RE1 (Chong et al. 1995; Schoenherr et al.
1996; Bruce et al. 2004; Johnson et al. 2006). The Bdnf
promoter contains an RE1-binding site that has previously
been shown to bind to and be regulated by REST both
in vitro and in vivo (Zuccato et al. 2001, 2003; Bruce et al.
2004) and recent work has highlighted a critical role for
REST in HD through its regulation of BDNF (Zuccato et al.
2007). Here, EMSA we show the ability of a modiﬁed
double-stranded ODNs that contains a canonical RE1 site to
block binding of REST to endogenous binding sites by
sequestration of REST protein and to subsequently rescue
levels of BDNF mRNA and protein in Hdh109/109 cells.
Moreover, using ChIP, we show that there is a concomitant
decrease in REST occupancy of the RE1 sites in the Bdnf
promoter and other target genes. In addition, a concomitant
local increase in H3K9ac is suggestive of a more open
chromatin environment characteristic of activated gene loci.
Collectively, these data show that modiﬁed decoy ODNs can
rescue REST-mediated transcriptional and epigenetic repres-
sion in an in vitro model of HD.
Decoy ODN can rescue REST target gene expression
including BDNF
Widespread transcriptional dysregulation is a central patho-
genic mechanism in HD and several transcription factors
have been implicated in this disease state (Zuccato et al.
2010). Perhaps, the most robust mechanistic link between
transcriptional dysfunction and the pathology of HD is
provided by REST (Zuccato and Cattaneo 2007). In vitro
studies have demonstrated that in normal cells, wild-type Htt
sequesters REST in the cytoplasm thereby preventing its
binding and repression of target genes (Zuccato et al. 2003).
However, in the presence of muHtt, this cytoplasmic
complex is disrupted and REST migrates to the nucleus
where it can bind to and repress its target genes. Although the
initial report focussed on the subsequent repression of the
BDNF gene (Zuccato et al. 2003), we have since demon-
strated that REST can binds to and repress numerous genes
whose expression is altered in the brain and periphery of HD
patients, many of which may also be involved in mediating
underlying pathological mechanisms (Zuccato et al. 2007;
Johnson et al. 2008b; Marullo et al. 2008). Although many
studies, including this study have used cell lines to study the
transcriptional effects of mutant Htt, it is important to realise
that levels of REST tend to be higher in progenitor lines than
differentiated neurons. Nevertheless, several studies have
indicated the presence of REST protein in the cytoplasm and
nucleus of differentiated neurons (Calderone et al. 2003;
Kuwabara et al. 2004; Sun et al. 2005; Spencer et al. 2006).
Furthermore, one recent study showed that endogenous
REST levels were sufﬁcient to repress a RE1-containing
BDNF promoter construct in cortical neurons (Hara et al.
2009). Accordingly, we propose that abrogation of REST
activity offers a potential strategy to rescue aberrantly
repressed REST target genes in differentiated neurons and
in HD might ultimately restore globally dysregulated neuro-
nal gene transcription.
Using adenoviral delivery of a dominant-negative form of
REST, we have previously shown that in addition to Bdnf,
other REST target genes dysregulated in HD, including Syn1
and Chrm4 (encoding synapsin-1 and the M4 muscarinic
receptor, respectively), are also de-repressed in parallel with
decreased REST occupancy at their RE1 sites (Greenway
et al. 2007; Zuccato et al. 2007; Johnson et al. 2008b). Here,
we show that transcription of these genes can also be
effectively de-repressed using a decoy ODN strategy, thus
offering an exciting alternative to the use of viral or plasmid
vectors. Further, the efﬁcacy of decoys relies only on having
access to the nuclear transcription factor, whereas dominant-
negative constructs based on DNA binding domains need to
access the chromatin of target genes.
REST acts as an epigenetic regulator in HD
One mechanism by which transcription can be impaired is
through altered nucleosome dynamics; in this context,
histone methylation and acetylation status is closely linked
with transcriptional activity, regulating transcription factor
access to promoter regions in DNA (Hake et al. 2004;
Shogren-Knaak et al. 2006). Recent studies have linked HD
transcriptional dysregulation to changes in histone modiﬁca-
tions (Sadri-Vakili et al. 2007; Kim et al. 2008), including
 2010 The Authors
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hypo-acetylation of histone H3 at promoters of down-
regulated genes in R6/2 mice (Sadri-Vakili et al. 2007).
Moreover, treatment with HDAC inhibitors corrects dysreg-
ulated gene expression through modiﬁcation of histone
proteins (Ferrante et al. 2003; Sadri-Vakili et al. 2007;
Thomas et al. 2008). This may prove to be of therapeutic
value in HD, particularly since several HDAC inhibitors are
already approved or being validated in clinical trials (for
recent review, see Copeland et al. 2010).
REST has been shown to interact with a number of
proteins by recruitment of co-repressor platforms via its N-
and C-terminal repressor domains (for review, see Ooi and
Wood 2007). Many of these proteins are required for REST
function via their enzymatic activities that serve to repress or
silence gene expression. For example, HDAC1 and HDAC2
are able to repress gene expression by removal of acetyl
groups on core histones, including H3K9 (Roopra et al.
2000; Ballas et al. 2001). Similarly REST recruits H3K4
demethylase activity in the form of lysergic acid diethyl-
amide 1, H3K9 methylase activity via G9a and chromatin
re-modelling activity, including brahma-related gene 1 and
BRAF35 (Battaglioli et al. 2002; Hakimi et al. 2002; Roopra
et al. 2004; Lee et al. 2005; Ooi et al. 2006). Therefore,
REST is able to both silence and repress neuronal genes by
creating a chromatin environment bearing a repressive local
epigenetic signature (Greenway et al. 2007).
Since REST repression in other in vitro systems has been
shown to be characterised by low levels of H3K9ac
(Greenway et al. 2007), we used ChIP to assess changes in
H3K9ac following delivery of our decoy ODNs into Hdh109/
109 cells. The low levels of H3K9ac observed around the RE1
sites of REST target genes in Hdh109/109 cells compared with
wild-type Hdh7/7 cells is in keeping with the parallel
decreases observed in gene expression and the reciprocally
increased occupancy of REST at these sites. ++D decoy-
transfected cells, however, showed signiﬁcantly increased
enrichment of H3K9ac at these loci to essentially wild-type
levels. These data suggest that REST may have a dual
function in target gene repression, including Bdnf, acting
both as a transcriptional repressor and epigenetic modulator.
This likely occurs through direct binding to its RE1 site and
subsequent modiﬁcation of the surrounding chromatin envi-
ronment. In this regard, we propose that REST may be
considered as much an epigenetic regulator as a transcrip-
tional repressor during the pathological state of HD.
Potential of modified decoy ODN technology in HD
Over 3000 REST binding sites have been identiﬁed in the
human and murine genomes, and many target genes encode
for proteins that are fundamental for neuronal development
and differentiation (Bruce et al. 2004; Johnson et al. 2006).
REST is the only known transcription factor able to bind the
highly conserved RE1 sequence. Owing to the speciﬁcity of
this binding and the long 21 bp length of the canonical RE1
sequence, modulation of aberrant REST function associated
with HD represents an ideal model for the application of
decoy ODN strategies. One of the main limitations of decoy
technology has been the rapid degradation of unmodiﬁed
ODNs by nuclease digestion (Gao et al. 1992; Brown et al.
1994). Different strategies have evolved to render the decoys
nuclease-resistant, such as the use of locked nucleic acids
(Crinelli et al. 2002) or addition of phosphorothiolated
nucleotides (Yang et al. 2002). We chose the latter approach
and used a phosphorothiolated decoy ODN based on a
canonical RE1 site (REST decoy) as deﬁned by previous
bioinformatic and ChIP studies (Bruce et al. 2004; Johnson
et al. 2006). Results presented here demonstrate that a
phosphorothiolated decoy is sufﬁciently stable and speciﬁc to
enable efﬁcient blockade of REST activity. In addition, our
results suggest that decoy ODNs are as effective at attenu-
ating REST activity as other previously employed strategies,
such as adenoviral delivery of DN : REST or transfection of
Rest shRNAs (Greenway et al. 2007; Zuccato et al. 2007
and data not shown). They also avoid the need for large DNA
constructs and viral delivery systems and they side-step the
issue of potential off-target effects encountered using RNAi
technology. Moreover, their ability to directly interfere with
transcription factor binding can be directly inferred by using
labelled ODNs to serve as probes in EMSAs (Hara et al.
2003; Kubo et al. 2003). With a ﬂuorescence-labelled decoy
ODN carrying the canonical RE1 sequence, we were able to
directly show the interaction between REST and the decoy
and we conﬁrmed the presence of REST in this complex
through the use of a speciﬁc anti-REST antibody to supershift
the protein/DNA complex.
Widespread gene dysregulation is a hallmark of HD and in
some cases precedes many of the well-known physical
symptoms of the disease (for recent review, see Buckley
et al. 2010). The functional products of many of these
dysregulated genes have provided new insights into possible
mechanisms underlying HD pathology, including the well-
known role of BDNF and concomitant loss of medium spiny
neurons (reviewed in Zuccato and Cattaneo 2007). As well as
transcriptional dysregulation, it is becoming increasingly
clear that epigenetic disruption occurs in HD and, indeed,
targeting HDAC activity has become a major platform for
HD drug development (Ryu et al. 2006; Kazantsev and
Hersch 2007; Kazantsev and Thompson 2008). Many REST
functions are attributed to its recruitment of HDAC activity
and it is likely that the causative role of REST in HD occurs
through an inextricable linkage of transcriptional and epige-
netic dysregulation (Buckley et al. 2010). The use of a
modiﬁed decoy strategy presented here that speciﬁcally
targets REST function provides a novel and effective means
by which it is possible to show effective rescue of both
transcriptional and epigenetic effects of REST in an in vitro
HD model; this included restoration of Bdnf gene and protein
expression and H3K9ac levels at its promoter. Modiﬁed
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decoys thus offer an attractive alternative to plasmid- or
viral-based vectors for interfering with target protein function
and provide an ideal strategy to investigate the contribution
of REST to HD pathology in well-established mouse models.
Perhaps, more intriguingly, since modiﬁed ODNs targeting
transcription factor function have been shown to be of
potential therapeutic value in other disorders (Kubo et al.
2003; De Stefano et al. 2010), they may be useful in future
clinical intervention for early-stage HD. The work presented
here presents a proof-of-concept that our decoy strategy is
capable of rescuing REST-mediated repression of neuronal
gene expression a cell line model of HD. Nevertheless, these
ﬁndings need to be taken forward and the effectiveness of
decoys needs to be tested in neuronal cells, where endo-
genous levels of REST are lower than those found in
Hdh cells. Future studies will address this by using in vivo
models of HD.
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